| Catalog No. |
TD-HP158016 |
| Species reactivity |
Human |
| Applications |
Research Grade Biosimilar |
| Host species |
Humanized |
| Isotype |
(scFv-kappa-heavy) -h- CH3 |
| Expression system |
Mammalian Cells |
| Clonality |
Monoclonal |
| Target |
T-cell surface glycoprotein CD8 alpha chain, CD8a, T-lymphocyte differentiation antigen T8/Leu-2, MAL, CD8A |
| Endotoxin level |
Please contact the lab for this information. |
| Purity |
>95% purity as determined by SDS-PAGE. |
| Purification |
Purified by ion exchange chromatography. |
| Accession |
P01732 |
| Form |
Liquid |
| Storage buffer |
0.01M PBS,pH7.4. |
| Stability and Storage |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
| Alternate Names |
89Zr-IAB22M2C,IAB22M2C,89Zr-Df-IAB22M2C,CAS:2611099-93-3 |
| Background |
Crefmirlimab is a humanized CD8 specific minibody. The minibody (Mb) maintains the specificity of full-length antibodies but has no immune effector functions and is biologically inert. |
| Note |
For research use only. Not for use in clinical or therapeutic applications. |